Skip to main content
. 2021 Jul 31;10(18):6227–6238. doi: 10.1002/cam4.4162

FIGURE 3.

FIGURE 3

The molecular diversity between sarcomatoid HCC and non‐sarcomatoid HCC. (A) The comparison of immunohistochemistry markers; (B) The overview of clinically relevant genomic alterations in two groups; (C) The differential genomic alterations between the two groups; (D) The comparison of druggable mutations